Objective While guidelines advocate renin-angiotensin system inhibitors (RASi) for renoprotection in lupus nephritis (LN), ...
Objective Hydroxychloroquine (HCQ) is a cornerstone therapy for SLE, reducing flares, organ damage and mortality. However, ...
Objective Belimumab has well-established efficacy in improving overall SLE disease activity and preventing flares and organ ...
Objective Psychological comorbidities are common in adolescents with SLE. Incorporating structured mental-health screening ...
Objective SLE is a heterogeneous systemic autoimmune disease with diverse clinical manifestations. We aimed to identify ...
Zucker School of Medicine at Hofstra/Northwell, New York, USA In summary, robust B-cell depletion with obinutuzumab was responsible for the attainment of significant effect sizes observed in NOBILITY ...
Low disease activity and remission are recognized as important goals in the treatment of patients with lupus and as valuable outcomes in epidemiological research and in clinical trials. The former is ...
For more than a century, certain bacterial infections that breach skin or mucosal barriers have been known to act as triggers of autoimmune syndromes, including rheumatic fever and post-streptococcal ...
Objectives To achieve consensus on domains of active disease for inclusion in a novel outcome measure for SLE randomised controlled trials (RCTs), the Treatment Response Measure for SLE (TRM-SLE).
Background Lupus nephritis (LN) is a severe and prevalent complication of SLE. Compound Muniziqi granule (CMG), a traditional remedy, is commonly used to treat immune system-related disorders. However ...
Objective To explore the efficacy of initial treatment of newly diagnosed childhood-onset lupus nephritis (cLN) with combination of belimumab and either cyclophosphamide, mycophenolate mofetil, ...
Objective Disease severity in SLE is an important concept related to disease activity, treatment burden and prognosis. We set out to evaluate if high disease activity status (HDAS), based on ever ...